1. Search Result
Search Result
Results for "

Nectin-4

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Fluorescent Dye

2

Peptides

6

Inhibitory Antibodies

19

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)
    1 Publications Verification

    Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv
    1 Publications Verification

    Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv
  • HY-P99016
    Enfortumab
    1 Publications Verification

    ADC Antibody Nectin-4 Cancer
    Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
    Enfortumab
  • HY-147271

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b) is an antibody-drug conjugate linker (ADC linker) that binds to Nectin-4 polypeptides conjugated to chemotherapeutic agents. Mal-PEG8-Val-Ala-PAB-Exatecan can be used for cancer research .
    Mal-PEG8-Val-Ala-PAB-Exatecan
  • HY-147270
    MC-VA-PAB-Exatecan
    1 Publications Verification

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity .
    MC-VA-PAB-Exatecan
  • HY-P991707

    SHR-A2102 antibody

    Nectin-4 Cancer
    Notiretatug is a humanized IgG1κ antibody targeting Nectin-4. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Notiretatug
  • HY-P991742

    15A7.5; ETx-22 Antibody

    ADC Antibody Cancer
    LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .
    LY4101174 Antibody
  • HY-P990977

    MW282 mAb

    Nectin-4 Inflammation/Immunology
    HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Bulumtatug
  • HY-178489

    Nectin-4 Cancer
    BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
    BGC1614
  • HY-RS09177

    Small Interfering RNA (siRNA) Others

    NECTIN4 Human Pre-designed siRNA Set A contains three designed siRNAs for NECTIN4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NECTIN4 Human Pre-designed siRNA Set A
    NECTIN4 Human Pre-designed siRNA Set A
  • HY-RS27764

    Small Interfering RNA (siRNA) Others
    Nectin4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nectin4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Nectin4 Rat Pre-designed siRNA Set A
    Nectin4 Rat Pre-designed siRNA Set A
  • HY-RS21247

    Small Interfering RNA (siRNA) Others

    Nectin4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nectin4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nectin4 Mouse Pre-designed siRNA Set A
    Nectin4 Mouse Pre-designed siRNA Set A
  • HY-P11837

    Biochemical Assay Reagents Cancer
    NECT-224 is a bifunctional chelator and a nectin-4 targeting peptide conjugate. NECT-224 can be used as a PET imaging agent when labeled with 64Cu or 68Ga .
    NECT-224
  • HY-P992133

    SYS6002 Antibody; CRB-701 Antibody

    ADC Antibody Nectin-4 Cancer
    Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Sutantatug

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: